睡眠障害の市場規模、シェア、成長分析：障害の種類別、製品別、最終用途別、地域別 - 産業予測 2025～2032年

睡眠障害市場規模は2023年に276億米ドルと評価され、2024年の303億9,000万米ドルから2032年には656億1,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは10.1％で成長する見通しです。

睡眠関連疾患の診断、治療、管理に焦点を当てた睡眠障害世界市場は、健康全般における睡眠の重要性に対する意識の高まりにより、大きな成長を遂げています。不眠症、睡眠時無呼吸症候群、レストレスレッグス症候群などの様々な疾患は、ストレスやライフスタイルの変化によってますます蔓延しています。革新的な診断ツールや遠隔医療ソリューションなどの技術的進歩も、市場拡大の原動力となっています。さらに、人口の高齢化、肥満や糖尿病などの慢性疾患の割合の増加が、効果的な介入に対する需要の高まりに寄与しています。その結果、製薬会社や医療機器メーカーは、より充実した治療法やソリューションを提供するための研究開発に多額の投資を行っており、健康における睡眠の重要な役割に対する認識の高まりを受けて、市場の上昇の勢いは確実に続いています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ
• 規制情勢
• 特許分析

睡眠障害市場規模：障害の種類別& CAGR（2025-2032）

• 市場概要
• 不眠症
• 睡眠時無呼吸症候群
• レストレスレッグス脚症候群
• ナルコレプシー
• 概日リズム障害

睡眠障害市場規模：製品別& CAGR（2025-2032）

• 市場概要
• 診断
• 治療薬

睡眠障害市場規模：最終用途別& CAGR（2025-2032）

• 市場概要
• 病院と睡眠研究室
• 在宅ケア施設と個人

睡眠障害市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Merck & Co., Inc.（USA）
• Mylan N.V.（USA）
• Pfizer Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Jazz Pharmaceuticals plc（Ireland）
• Sanofi（France）
• GlaxoSmithKline plc（UK）
• Eli Lilly and Company（USA）
• Becton, Dickinson and Company（USA）
• Koninklijke Philips N.V.（Netherlands）
• ResMed Inc.（USA）
• Fisher & Paykel Healthcare Corporation Limited（New Zealand）
• Natus Medical Incorporated（USA）
• Compumedics Limited（Australia）
• Vyaire Medical, Inc.（USA）
• SomnoMed Limited（Australia）
• Drive DeVilbiss Healthcare（USA）
• Cadwell Industries, Inc.（USA）

結論と提言

Sleep Disorder Market size was valued at USD 27.6 billion in 2023 and is poised to grow from USD 30.39 billion in 2024 to USD 65.61 billion by 2032, growing at a CAGR of 10.1% during the forecast period (2025-2032).

The Global Sleep Disorder Market, focused on diagnosing, treating, and managing sleep-related conditions, is experiencing significant growth due to heightened awareness of the importance of sleep for overall health. Various disorders such as insomnia, sleep apnea, and restless legs syndrome are becoming increasingly prevalent due to stress and changing lifestyles. Technological advancements, including innovative diagnostic tools and telemedicine solutions, are also driving market expansion. Additionally, the aging population and rising rates of obesity and chronic conditions like diabetes contribute to the growing demand for effective interventions. As a result, pharmaceutical companies and medical device manufacturers are heavily investing in research and development to deliver enhanced therapies and solutions, ensuring the market's upward momentum continues in response to the growing recognition of sleep's vital role in health.

Top-down and bottom-up approaches were used to estimate and validate the size of the Sleep Disorder market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Sleep Disorder Market Segments Analysis

Global Sleep Disorder Market is segmented by Disorder Type, Product, End-use and region. Based on Disorder Type, the market is segmented into Insomnia, Sleep Apnea, Restless Legs Syndrome, Narcolepsy and Circadian Rhythm Disorders. Based on Product, the market is segmented into Diagnostics and Therapeutics. Based on End-use, the market is segmented into Hospitals & Sleep Laboratories and Home Care Settings & Individuals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Sleep Disorder Market

An important catalyst for the growth of the sleep disorder market is the rising awareness regarding the detrimental health effects associated with these conditions. As education and information are circulated through numerous platforms, a significant number of individuals are becoming more informed about the importance of addressing sleep-related concerns. This heightened awareness encourages people to pursue proper diagnosis and treatment, leading to an increased demand for sleep disorder solutions. Consequently, as the public becomes more cognizant of how sleep disorders can affect overall health and quality of life, the market for effective treatments and interventions is expected to expand.

Restraints in the Sleep Disorder Market

The sleep disorder market faces significant restraints due to the persistent stigma surrounding these conditions, which discourages many individuals from pursuing professional assistance. This societal perception can result in delayed treatment and worsening symptoms. Furthermore, in various regions, a general lack of awareness about sleep disorders impedes timely diagnosis and intervention, leaving many sufferers without the help they need. This combination of stigma and insufficient awareness not only affects individual health outcomes but also poses challenges for the overall growth of the sleep disorder market, as potential patients may remain unaware of the resources and support available to them.

Market Trends of the Sleep Disorder Market

The sleep disorder market is experiencing a significant trend toward telemedicine and remote monitoring, driven largely by the COVID-19 pandemic. Consumers are increasingly seeking convenient access to sleep disorder diagnosis and treatment, leading to the emergence of virtual sleep clinics and advanced wearable technologies that facilitate real-time sleep tracking from home. This shift not only enhances patient engagement but also reduces barriers to care, making it easier for individuals to seek help. As awareness of sleep disorders grows, along with the demand for personalized and accessible healthcare solutions, the market is projected to expand rapidly, reinforcing the critical role of technology in sleep health management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Sleep Disorder Market Size by Disorder Type & CAGR (2025-2032)

• Market Overview
• Insomnia
• Sleep Apnea
• Restless Legs Syndrome
• Narcolepsy
• Circadian Rhythm Disorders

Global Sleep Disorder Market Size by Product & CAGR (2025-2032)

• Market Overview
• Diagnostics
• Therapeutics

Global Sleep Disorder Market Size by End-use & CAGR (2025-2032)

• Market Overview
• Hospitals & Sleep Laboratories
• Home Care Settings & Individuals

Global Sleep Disorder Market Size & CAGR (2025-2032)

• North America (Disorder Type, Product, End-use)
  • US
  • Canada
• Europe (Disorder Type, Product, End-use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disorder Type, Product, End-use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disorder Type, Product, End-use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disorder Type, Product, End-use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Koninklijke Philips N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ResMed Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fisher & Paykel Healthcare Corporation Limited (New Zealand)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natus Medical Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Compumedics Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vyaire Medical, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SomnoMed Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Drive DeVilbiss Healthcare (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cadwell Industries, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations